Equities researchers at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research report issued on Friday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Trading Down 2.6 %
PULM opened at $1.84 on Friday. The company has a market cap of $6.72 million, a price-to-earnings ratio of -0.48 and a beta of 0.90. The stock has a fifty day simple moving average of $1.87 and a two-hundred day simple moving average of $1.88. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $3.05.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%. The business had revenue of $2.20 million during the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
See Also
- Five stocks we like better than Pulmatrix
- Quiet Period Expirations Explained
- Roblox: The Bottom Just Fell Out of the Metaverse
- How to Start Investing in Real Estate
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- What are earnings reports?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
